Skip to main content
NCBI home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 1999 Jun 22;13(4):166–172. doi: 10.1002/(SICI)1098-2825(1999)13:4<166::AID-JCLA5>3.0.CO;2-X

Insulin‐like growth factors (IGF‐I, free IGF‐I, and IGF‐II) and insulin‐like growth factor binding proteins (IGFBP‐2, IGFBP‐3, IGFBP‐6, and ALS) in blood circulation

Herbert Yu 1,✉, Jehangir Mistry 2, Michael J Nicar 2, M Javad Khosravi 3, Anastasia Diamandis 3, Jaap van Doorn 4, Anders Juul 5
PMCID: PMC6808158  PMID: 10414596

Abstract

Insulin‐like growth factors (IGFs) and IGF binding proteins (IGFBPs) play an important role in cell growth and differentiation. Clinical and epidemiological studies have indicated that measuring IGFs and IGFBPs in blood has potential implications in assessing growth‐related abnormalities and risks of certain types of cancer. To facilitate the application, we reported a large collection of reference ranges of IGFs and IGFBPs in normal population and evaluations of these molecules in serum and plasma as well as the impact of freeze‐thaw cycles on the measurement. IGF‐I, IGFBP‐3 and ALS showed a similar pattern of change associated with age. Levels of these molecules were low at birth and increased with age through puberty. After puberty the levels declined slowly with age. Overall, IGF‐I, IGFBP‐3 and ALS were slightly higher in females than in males. Free IGF‐I accounted for about 1% of the total IGF‐I and its variation with age was similar to total IGF‐I. IGF‐II levels were also increased with age from birth to puberty, but became stable after puberty. There was little difference in IGF‐II levels between genders. IGFBP‐2 levels declined with age from birth to puberty. Levels of IGFBP‐6 in contrast were increased with age. These IGF binding proteins were higher in males than in females. IGFs, IGFBP‐3 and ALS were 5‐10% higher in serum than in plasma. IGFBP‐2 and IGFBP‐6 differed substantially between serum and plasma. Freeze‐thaw treatment up to five cycles had little impact on plasma levels of IGFs and IGFBP‐3. Our observations suggest that levels of IGFs and their binding proteins are varied with age, gender, and types of specimen and that these variations need to be taken into consideration when IGFs and their binding proteins are utilized in clinic and research. J. Clin. Lab. Anal. 13:166–172, 1999. © 1999 Wiley‐Liss, Inc.

Keywords: IGFs; free IGF‐I, IGFBP‐2, IGFBP‐3; IGFBP‐6; ALS

REFERENCES

  • 1. Daughaday WH, Rotwein P. Insulin‐like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68–90. Medline [DOI] [PubMed] [Google Scholar]
  • 2. Jones JI, Clemmons DR. Insulin‐like growth factors and their binding proteins: biological antions. Endocr Rev 1995;16:3–34. Medline [DOI] [PubMed] [Google Scholar]
  • 3. Macaulay VM. Insulin‐like growth factors and cancer. Br J Cancer 1992;65:311–320. Medline [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. LeRoith D, Werner H, Beitner‐Johnson D, Roberts CT. Molecular and cellular aspects of the insulin‐like growth factor I receptor. Endocr Rev 1995;16:143–163. Medline [DOI] [PubMed] [Google Scholar]
  • 5. Shimasaki S, Ling N. Identification and molecular characterization of insulin‐like growth factor binding proteins (IGFBP‐1, ‐2, ‐3, ‐4, ‐5, and ‐6). Prog Growth Factor Res 1991;1:243–266. [DOI] [PubMed] [Google Scholar]
  • 6. Baxter RC. Characterization of the acid‐labile subunit of the growth hormone dependent insulin‐like growth factor binding protein complex. J Clin Endocrinol Metab 1988;67:265–272. Medline [DOI] [PubMed] [Google Scholar]
  • 7. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin‐like growth factor binding protein complex, purification properties of the acid‐labile subunit from human serum. J Biol Chem 1989;264:11843–11848. Medline [PubMed] [Google Scholar]
  • 8. Cuneo RC, Hickman PE, Wallace JD, et al. Altered endogenous growth hormone secretory kinetics and diurnal GH‐binding protein profiles in adults with chronic liver disease. Clin Endocr 1995;43:265–275. Medline [DOI] [PubMed] [Google Scholar]
  • 9. Holt RI, Jones JS, Stone NM, Baker AJ, Miell JP. Sequential changes in insulin‐like growth factor I (IGF‐I) and IGF‐binding proteins in children with end‐stage liver disease before and after successful orthotopic liver transplantation. J Clin Endocrinol Metab 1996;81:160–168. Medline [DOI] [PubMed] [Google Scholar]
  • 10. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. Insulin‐like growth factors I and II in evaluation of growth retardation. J Pediatr 1986;109:428–433. Medline [DOI] [PubMed] [Google Scholar]
  • 11. Cohen P, Rosenfeld RG. Physiologic and clinical relevance of the insulin‐like growth factor binding proteins. Curr Opin Pediatr 1994;6:462–467. Medline [DOI] [PubMed] [Google Scholar]
  • 12. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE. Evaluation of acromegaly by radio‐immunoassay of somatomedin‐C. N Engl J Med 1979;301:1138–1142. Medline [DOI] [PubMed] [Google Scholar]
  • 13. Jorgensen JO, Moller N, Moller J, Weeke J, Blum WF. Insulin‐like growth factors (IGF)‐I and ‐II and IGF binding protein‐1, ‐2, and ‐3 in patients with acromegaly before and after adenomectomy. Metabolism 1994;43:579–583. Medline [DOI] [PubMed] [Google Scholar]
  • 14. Hankinson S, Willett WC, Colditz GA, et al. Circulating concentration of insulin‐like growth factor‐I and risk of breast cancer. Lancet 1998;351:1393–1396. Medline [DOI] [PubMed] [Google Scholar]
  • 15. Bruning PF, van Doorn J, Bonfrer JMG, et al. Insulin‐like growth‐factor‐binding protein 3 is decreased in early‐stage operable pre‐menopausal breast cancer. Int J Cancer 1995;62:266–270. Medline [DOI] [PubMed] [Google Scholar]
  • 16. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin‐like growth factor‐I and prostate cancer risk: a prospective study. Science 1998;279:563–566. Medline [DOI] [PubMed] [Google Scholar]
  • 17. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin‐like growth factor 1 and prostate cancer risk: a population‐based case‐control study. J Natl Cancer Inst 1998;90:911–915. Medline [DOI] [PubMed] [Google Scholar]
  • 18. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. High plasma levels of insulin‐like growth factor‐I in association with lung cancer risk, a case‐control analysis. J Natl Cancer Inst 1999;91:151–156. Medline [DOI] [PubMed] [Google Scholar]
  • 19. Van Hooft IM, Grobbee, DE , Hofman A, Valkenberg HA. Early prediction of primary hypertension: an epidemiological approach. Int J Epidemiol 1988;17:228–229. Medline [DOI] [PubMed] [Google Scholar]
  • 20. Van Hooft IM, Schiffers P, Grobbee DE, Rahn KH, Hofman A. Similar plasma atrial natriuretic factor levels in children and young adults with a high and low probability of developing hypertension: the Dutch hypertension and offspring study. J Hypertens Suppl 1989;7:43–44. [DOI] [PubMed] [Google Scholar]
  • 21. Juul A, Holm K, Kastrup KW, et al. Free insulin‐like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. J Clin Endocrinol Metab 1997;82:2497–2502. Medline [DOI] [PubMed] [Google Scholar]
  • 22. Juul A, Moller S, Mosfeldt‐Laursen E, et al. The acid‐labile subunit of human ternary insulin‐like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects and diagnostic use in patients with GH deficiency. J Clin Endocrinol Metab 1998;83:4408–4415. Medline [DOI] [PubMed] [Google Scholar]
  • 23. Khosravi MJ, Diamandi A, Mistry J, Lee PDK. Noncompetitive ELISA for human serum insulin like growth factor‐I. Clin Chem 1996;42:1147–1154. Medline [PubMed] [Google Scholar]
  • 24. Khosravi MJ, Diamandi A, Mistry J, Krishna RG, Khare A. Acid‐labile subunit of human insulin‐like growth factor‐binding protein complex: measurement, molecular, and clinical evaluation. J Clin Endocrinol Metab 1997;82:3944–3951. Medline [DOI] [PubMed] [Google Scholar]
  • 25. Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin‐like growth factor (IGF)‐binding protein‐3 (IGFBP‐3) in healthy infants, children, and adolescents: the relation to IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534–2542. Medline [DOI] [PubMed] [Google Scholar]
  • 26. Argente J, Barrios V, Pozo J, et al. Normative data for insulin‐like growth factors (IGFs), IGF‐binding proteins, and growth hormone‐binding protein in a healthy Spanish pediatric population: age‐ and sex‐related changes. J Clin Endocrinol Metab 1993;77:1522–1528. Medline [DOI] [PubMed] [Google Scholar]
  • 27. Porch JV, Jain K, Reilly A, et al. Aging, physical activity, insulin‐like growth factor I, and body composition in Guatemalan women. Am J Clin Nutrit 1997;66:874–879.Medline [DOI] [PubMed] [Google Scholar]
  • 28. Nystrom FH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE, Arnqvist HJ. Population‐based reference values for IGF‐I and IGF‐binding protein‐1: relations with metabolic and anthropometric variables. Euro J Endocrinol 1997;136:165–172.Medline [DOI] [PubMed] [Google Scholar]
  • 29. Landin‐Wilhelmsen K, Wilhelmsen L, Lappas G, et al. Serum insulin‐like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol 1994;41:351–357.Medline [DOI] [PubMed] [Google Scholar]
  • 30. Kitano M, Shimizu T, Yamazaki Y, Umezu Y, Arakawa Y, Daimon Y. Serum insulin‐like growth factor‐I (IGF‐I) in normal Japanese adults. Endocr J 1995;42:767–770. Medline [DOI] [PubMed] [Google Scholar]
  • 31. Juul A, Bang P, Hertel NT, et al. Serum insulin‐like growth factor‐I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1994;78:744–752. Medline [DOI] [PubMed] [Google Scholar]
  • 32. Blum WF, Norn N, Kratzsch J, et al. Clinical studies of IGFBP‐2 by radioimmunoassay. Growth Regul 1993;3:100–104. Medline [PubMed] [Google Scholar]
  • 33. van Doorn J, Ringeling AM, Shmueli SS, Hokken‐Koelega ACS, van Buul‐Offers, Jansen M. Circulating levels of insulin‐like growth factor binding protein‐6 (IGFBP‐6) in health and disease as determined by radioimmunoassay. The 79th annual meeting of the Endocrine Society, program and abstracts; 1998. [DOI] [PubMed]
  • 34. Thoren M, Hilding A, Baxter RC, Degerblad M, Wivall‐Helleryd IL, Hall K. Serum insulin‐like growth factor I (IGF‐I), IGF‐binding protein‐1 and ‐3, and the acid‐labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1997;82:223–228. Medline [DOI] [PubMed] [Google Scholar]
  • 35. Arai T, Busby W, Clemmons DR. Binding of insulin‐like growth factor (IGF) I or II to IGF‐binding protein‐2 enables it to bind to heparin and extracellular matrix. Endocrinology 1996;137:4571–4575. Medline [DOI] [PubMed] [Google Scholar]
  • 36. Russo VC, Bach LA, Fosang AJ, Baker NL, Werther GA. Insulin‐like growth factor binding protein‐2 binds to cell surface proteoglycans in the rat brain olfactory bulb. Endocrinology 1997;138:4858–486 Medline [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES